Stipple Bio leverages its Pointillist Platform to discover tumor-specific cell surface epitopes and develop precision oncology medicines designed to minimize on-target/off-tumor toxicity. Its lead candidate, STP-100, is a novel antibody-drug conjugate (ADC) incorporating tumor-specific binders and is expected to enter clinical studies in early 2027. The company plans to use its Series A proceeds to advance STP-100 into multiple early-stage clinical trials and to expand its pipeline by identifying additional high therapeutic-index targets. Stipple Bio was founded in 2022 by Dr. Aaron Ring and Dr. Aashish Manglik and is led by CEO Jeff Landau. The company recently added Derek DiRocco, PhD and Thilo Schroeder, PhD to its board and retains board members including Vineeta Agarwala and Greg Verdine. Stipple Bio raised $100M in its Series A round announced in April 2026.

Total raised

$100M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2026